Application of remazolam in catheter radiofrequency ablation anesthesia in patients with atrial fibrillation

Effect of remazolam in catheter radiofrequency ablation anesthesia in patients with atrial fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500099007

Enrollment

Unknown

Registered

2025-03-17

Start date

2024-02-07

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Group R :Remazolam

Group P:Propofol

Eligibility

Sex/Gender

All

Age

45 Years to 76 Years

Inclusion criteria

Inclusion criteria: Patients with atrial fibrillation undergoing radiofrequency catheter ablation have no gender limit, ages 45-76 years old, BMI 18-25kg/m2, ASA grade I-II.

Exclusion criteria

Exclusion criteria: Possible allergies to anesthetic drugs such as propofol, remazolam, refentanyl, etc., heart failure, severe respiratory diseases, mental or neurological diseases, liver and kidney dysfunction, sleep apnea syndrome, and difficult airways .

Design outcomes

Primary

Measure	Time frame
Number of respiratory depression cases;	—

Secondary

Measure	Time frame
Heart rate;blood pressure;Oxygen saturation;Respiration frequency;Cough and movement cases;Electrophysiology doctor satisfaction;Radio frequency ablation operation time;X-ray exposure time;Wake time;	—

Countries

China

Contacts

Public ContactChen Xu

Shanghai First People's Hospital Jiuquan Hospital(Jiuquan People's Hospital)

xuzidao@126.com+86 139 9371 9695

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026